General recommendations on immunization: Recommendations of the advisory committee on immunization practices (ACIP)

Morbidity and Mortality Weekly Report

Volumn 60, Issue RR-2, 2011, Pages 3-61

  Kroger, Andrew T ^a   Sumaya, Ciro V ^b   Pickering, Larry K ^a   Atkinson, William L ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79551646111     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (239)

1. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001;20:63-75.
2. CDC. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8).
3. Watson JC, Pearson JA, Markowitz LE, et al. An evaluation of measles revaccination among school-entry-aged children. Pediatrics 1996;97: 613-8.
4. CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-4).
5. CDC. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR 2008;57(No. RR-3).
6. Levine L, Edsall G. Tetanus toxoid: what determines reaction proneness [Letter]. J Infect Dis 1981;144:376.
7. Edsall G, Elliot MW, Peebles TC, Levine L, Eldred MC. Excessive use of tetanus toxoid boosters. JAMA 1967;202:17-9.
8. National Vaccine Advisory Committee. Standards for child and adolescent immunization practices. Pediatrics 2003;112:958-63.
9. Hutchins SS, Escolan J, Markowitz LE, et al. Measles outbreak among unvaccinated preschool-age children: opportunities missed by health care providers to administer measles vaccine. Pediatrics 1989;83: 369-74.
10. Deforest A, Long SS, Lischner HW, et al. Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics 1988;81: 237-46.
11. King GE, Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J 1994;13:394-407.
12. Dashefsky B, Wald E, Guerra N, Byers C. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type B conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Pediatrics 1990;85:682-9.
13. Giammanco G, Li Volti S, Mauro L, et al. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine 1991;9:747-50.
14. CDC. Typhoid immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994;43 (No. RR-14).
15. DeStefano F, Goodman RA, Noble GR, McClary GD, Smith SJ, Broome CV. Simultaneous administration of influenza and pneumococcal vaccines. JAMA 1982;247:2551-4.
16. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR 2006;55(No. RR-17).
17. Yvonnet B, Coursaget P, Deubel V, Diop-Mar I, Digoutte JP, Chiron J. Simultaneous administration of hepatitis B and yellow fever vaccines. J Med Virol 1986;19:307-11.
18. Stefano I, Sato HK, Pannuti CS, et al. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 1999;17:1042-6.
19. CDC. Yellow fever vaccine: recommendations of the Immunization Practices Advisory Committee (ACIP), 2010. MMWR 2010:59 (No. RR-7).
20. CDC. Recommended immunization schedules for persons aged 0 through 18 years-United States, 2011. MMWR 2011;60(5).
21. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999;18:757-63.
22. CDC. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older: recommendations of the ACIP. MMWR 1991;40 (No. RR-1).
23. CDC. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46 (No. RR-7).
24. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-3).
25. CDC. Prevention of pneumococcal disease among infants and young children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(No. RR-11).
26. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); part 1: immunization of infants, children, and adolescents. MMWR 2005;54(No. RR-16).
27. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommended childhood and adolescent immunization schedules-United States, 2010. Pediatrics 125:195-6.
28. CDC. Recommended adult immunization schedule-United States, 2011. MMWR 2011;60(4).
29. Woodin KA, Rodewald LE, Humiston SG, Carges MS, Schaffer SJ, Szilagyi PG. Physician and parent opinions: are children becoming pincushions from immunizations? Arch Pediatr Adolesc Med 1995;149: 845-9.
30. Kuppermann M, Nease RF, Ackerson LM, et al. Parents' preferences for outcomes associated with childhood vaccinations. Pediatr Infect Dis J 2000;19:129-33.
31. Meyerhoff A, Jacobs RJ, Greenberg DP, Yagoda B, Castles CG. Clinician satisfaction with vaccination visits and the role of multiple injections: results from the COVISE study (Combination Vaccines Impact on Satisfaction and Epidemiology). Clin Pediatr 2004;43:87-93.
32. Marshall GS, Happe LE, Lunacsek, OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007; 26:496-500.
33. Kalies H, Grote V, Verstraeten T, et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507-12.
34. Happe LE, Lunacsek OE, Kruzikas DT, et al. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J 2009;28:98-101.
35. CDC. Recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR 2010;59(No. RR-3).
36. Thompson LA, Irigoyen M, M LA, et al. The impact of DTaP-IPV-HB vaccine on use of health services for young infants. Pediatr Infect Dis J 2006;25:826-31.
37. Denoel PA, Goldblatt D, de Vleeshauwer I, et al. Quality of the Haemophilus influenza type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin Vaccine Immunol 2007;14:1362-9.
38. Weniger BG, Chen RT, Jacobsen SH, et al. Addressing the challenges to immunization practice with an economic algorithm for vaccine selection. Vaccine 1998;16:1885-97.
39. CDC. Notice to readers. FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine. MMWR 1997;46:107-9.
40. CDC. FDA approval of a Haemophilus b conjugate vaccine combined by reconstitution with an acellular pertussis vaccine. MMWR 1996;45:993-5.
41. CDC. Notice to readers: FDA approval for a combined hepatitis A and B vaccine. MMWR 2001;50:806-7.
42. CDC. Notice to readers. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants. MMWR 2003;52:203-4.
43. CDC. Notice to readers. Licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine. MMWR 2005;54: 1212-4.
44. CDC. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR 2008;57:1078-9.
45. CDC. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and Haemophilus b conjugate vaccine and guidance for use in infants and children. MMWR 2008;57:1079-80.
46. Plotkin S. Correlates of vaccine-induced immunity. Clin Infec Dis 2008; 47: 401-9.
47. Midthun K, Horne AD, Goldenthal KL. Clinical safety evaluation of combination vaccines. Dev Biol Stand 1998;95:245-9.
48. Pichichero ME. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002;21:854-9.
49. CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46 (No. RR-8).
50. CDC. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991;40 (RR-10).
51. CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54 (RR-7).
52. Petralli JK, Merigan TC, Wilbur JR. Action of endogenous interferon against vaccinia infection in children. Lancet 1965;2:401-5.
53. Petralli, JK, Merigan TC, Wilbur JR. Circulating interferon after measles vaccination. N Engl J Med 1965;273:198-201.
54. Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003;112:98-103.
55. CDC. Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices. MMWR 2008;57(No. RR-5).
56. Siber GR, Werner BC, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993;122: 204-11.
57. Mason W, Takahashi M, Schneider T. Persisting passively acquired measles antibody following gamma globulin therapy for Kawasaki disease and response to live virus vaccination [Abstract 311]. Presented at the 32nd meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy; Los Angeles, California; October 1992.
58. Kaplan JE, Nelson DB, Schonberger LB, et al. Effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ 1984;62:585-90.
59. Black NA, Parsons A, Kurtz JB, McWhinney N, Lacey A, Mayon-White RT. Post-partum rubella immunization: a controlled trial of two vaccines. Lancet 1983;2:990-2.
60. CDC. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR 2001;50(No. RR-12).
61. Siber GR, Snydman DR. Use of immune globulin in the prevention and treatment of infections. In: Remington J, Swartz M, eds. Current clinical topics in infectious diseases, vol. 12. Oxford: Blackwell Scientific; 1992.
62. Greenberg DP, Lieberman JM, Marcy SM, et al. Enhanced antibody responses in infants given different sequences of heterogeneous Haemophilus influenzae type b conjugate vaccines. J Pediatr 1995;126: 206-11.
63. Anderson EL, Decker MD, Englund JA, et al. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA 1995; 273:849-53.
64. Piazza M, Abrescia N, Picciotto L, et al. Demonstration of the interchangeability of 2 types of recombinant anti-hepatitis-B vaccine. Boll Soc Ital Biol Sper 1993;69:273-80.
65. Bryan JP, Henry CH, Hoffman AG, et al. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2000;19:743-50.
66. Greenberg DP, Pickering LK, Senders SD, et al. Interchangeability of two diphtheria-tetanus-acellular pertussis vaccines in infancy. Pediatrics 2002;109:666-72.
67. CDC. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-13).
68. CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59(No. RR-8).
69. Szilagyi PG, Rodewald LE. Missed opportunities for immunizations: a review of the evidence. J Public Health Manag Pract 1996;2:18-25.
70. Halsey NA, Boulos R, Mode F, et al. Response to measles vaccine in Haitian infants 6 to 12 months old: influence of maternal antibodies, malnutrition, and concurrent illnesses. N Engl J Med 1985; 313:544-9.
71. Ndikuyeze A, Munoz A, Stewart S, et al. Immunogenicity and safety of measles vaccine in ill African children. Int J Epidemiol 1988; 17:448-55.
72. Lindegren ML, Atkinson WA, Farizo VM, Stehr-Green PA. Measles vaccination in pediatric emergency departments during a measles outbreak. JAMA 1993;270:2222-3.
73. Atkinson W, Markowitz L, Baughman A, et al. Serologic response to measles vaccination among ill children [Abstract 422]. Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 1992; Anaheim, California.
74. Orenstein WA, Rodewald LE, Hinman AR, Schuchat A. Immunization in the United States. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA, eds. 5th ed. China: Saunders/Elsevier; 2008.
75. Lewis T, Osborn LM, Lewis K, Brockert J, Jacobsen J, Cherry JD. Influence of parental knowledge and opinions on 12-month diphtheria, tetanus, and pertussis vaccination rates. Am J Dis Child 1988; 142:283-6.
76. Farizo KM, Stehr-Green PA, Markowitz LE, Patriarca PA. Vaccination levels and missed opportunities for measles vaccination: a record audit in a public pediatric clinic. Pediatrics 1992;89:589-92.
77. CDC. Syncope after vaccination-United States, January 2005-July 2007. MMWR 2008;57:457-60.
78. Liebermann P. Anaphylaxis and anaphylactoid reactions. In: Middleton's allergy: principles and practice. Adkinson NF, Yunginger JW, Busse LW, Bochner BS, Holgate ST, Simons FE, eds. 6th ed. Philadelphia, PA: Mosby; 2003.
79. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999;103:321-5.
80. Brotherton JM, Gold MS, Kemp AS et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008;179: 525-33.
81. Ruggeberg JU, Gold MS, Bayas J, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5675-5684.
82. Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005;115:584-91.
83. Mosby's Drug Consult. 16th ed. Elsevier St Louis, MO; 2003. [Epinephrine.]
84. CDC. Update: vaccine side effects, adverse reactions, contraindications, and precautions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996;45(No. RR-12).
85. CDC. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR 2002;51(No. RR-16).
86. Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens; needlesticks and other sharps injuries; final rule (29 CFR Part 1910). Federal Register January 18, 2001;66:5318-25. Available at http://www.osha.gov/FedReg_osha_pdf/FED20010118A.pdf.
87. Drucker E, Alcabes PG, Marx PA. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet 2001;358:1989-92.
88. International Health Care Worker Safety Center. List of safety-engineered sharp devices and other products designed to prevent occupational exposures to bloodborne pathogens. Charlottesville, VA: University of Virginia; 2001. Available at http://www.healthsystem.virginia.edu/internet/epinet/safetydevice.cfm.
89. National Alliance for the Primary Prevention of Sharps Injuries. NAPPSI: National Alliance for the Primary Prevention of Sharps Injuries. Carlsbad, CA: NAPPSI; 2001. Available at http://www.nappsi.org.
90. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425-30.
91. Zuckerman JN. Importance of injecting vaccines into muscle: different patients need different needle sizes. Brit Med J 2000;321:1237-8.
92. Ipp MM, Gold R, Goldback M, et al. Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics 1989;83:679-82.
93. Michaels L, Poole RW. Injection granuloma of the buttock. Can Med Assoc J 1970;102:626-8.
94. Haramati N, Lorans R, Lutwin M, Kaleya RN. Injection granulomas: intramuscle or intrafat? Arch Fam Med 1994;3:146-8.
95. Bergeson PS, Singer SA, Kaplan AM. Intramuscular injections in children. Pediatrics 1982;70:944-8.
96. Poland GA, Borrund A, Jacobson RM, et al. Determination of deltoid fat pad thickness: implications for needle length in adult immunization. JAMA 1997;277:1709-11.
97. Groswasser J, Kahn A, Bouche B, Hanquinet S, Perlmuter N, Hessel L. Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness. Pediatrics 1997;100:400-3.
98. Ipp M, Taddio A, Sam J, et al. Vaccine-related pain: randomized controlled trial of two injection techniques. Arch Dis Child 2007; 92:1105-8.
99. Middleman AB, Anding R, Tung C. Effect of needle length when immunizing obese adolescents with Hepatitis B vaccine. Pediatrics 2010;125:e1-e5.
100. Scheifele D, Bjornson G, Barreto L, Meekison W, Guasparini R. Controlled trial of Haemophilus influenzae type b diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection. Vaccine 1992;10:455-60.
101. Hingson RA, Davis HS, Rosen M. Historical development of jet injection and envisioned uses in mass immunization and mass therapy based upon two decades' experience. Mil Med 1963;128:516-24.
102. Weniger BG, Papania MJ. Alternative vaccine delivery methods [Chapter 61]. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 5th ed. China: Saunders/Elsevier;2008;135
103. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999;77:789-800.
104. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999;77:801-7.
105. CDC. Hepatitis B associated with jet gun injection-California. MMWR 1986;35:373-6.
106. Canter J, Mackey K, Good LS, et al. Outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch Intern Med 1990;150:1923-7.
107. Hoffman PN, Abuknesha RA, Andrews NJ, Samuel D, Lloyd JS. Model to assess the infection potential of jet injectors used in mass immunization. Vaccine 2001;19:4020-7.
108. Kelly K, Loskutov A, Zehrung D, et al. Preventing contamination between injections with multiple-use nozzle needle-free injectors: A safety trial. Vaccine 2008;26:1344-52.
109. Gray L, Watt L, Blass EM. Skin-to-skin contact is analgesic in healthy newborns. Pediatrics 2000;105:1-6.
110. Gray L, Miller LW, Philipp BL, Blass EM. Breastfeeding is analgesic in healthy newborns. Pediatrics 2002;109:590-3.
111. Taddio A, Nulman I, Goldbach M, Ipp M, Koren G. Use of lidocaine-prilocaine cream for vaccination pain in infants. J Pediatr 1994; 124:643-8.
112. Uhari M. Eutectic mixture of lidocaine and prolocaine for alleviating vaccination pain in infants. Pediatrics 1993;92:719-21.
113. Halperin SA, McGrath P, Smith B, Houston T. Lidocaine-prilocaine patch decreases the pain associated with subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. J Pediatr 2000;136:789-94.
114. Frayling IM, Addison GM, Chatterge K, Meakin G. Methaemoglobinaemia in children treated with prilocaine-lignocaine cream. Brit Med J 1990;301:153-4.
115. Reis E, Holubkov R. Vapocoolant spray is equally effective as EMLA cream in reducing immunization pain in school-aged children. Pediatrics 1997;100:1-6.
116. American Academy of Pediatrics: Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics. 2008;1 21:1281-6.
117. Cook IF, Murtagh J. Comparative immunogenicity of hepatitis B vaccine administered into the ventrogluteal area and anterolateral thigh in infants. J Paediatr Child Health 2002:38;393-6.
118. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B vaccine: a cost reduction strategy. JAMA 1985;254:3203-6.
119. Coleman PJ, Shaw FE, Serovich J, Hadler SC, Margolis HS. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991;9:723-7.
120. Fishbein DB, Sawyer LA, Reid-Sanden FL, Weir EH. Administration of human diploid-cell rabies vaccine in the gluteal area [Letter]. N Eng J Med 1988;318:124-5.
121. CDC. Inadvertent misadministration of meningococcal conjugate vaccine-United States, June-August 2005. MMWR 2006;55: 101-7.
122. Belshe BB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-94.
123. CDC. Guidelines for maintaining and managing the vaccine cold chain. MMWR 2003;52:1023-5.
124. Langley A, Grant S, ed. Proceedings of the National Vaccine Storage Workshop; June 28-30, 2004; Brisbane, Australia. Maroochydore: Queensland Health; 2004.
125. Department of Health and Ageing. National vaccine storage guidelines: Strive for 5. Canberra: Commonwealth of Australia; 2005.
126. Atkinson WL, Kroger AT, Pickering LK. General immunization practices. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA. eds. 5th ed. China: Saunders/Elsevier; 2008.
127. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005;41:189-93.
128. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept. Clin Infect Dis 2005;41:199-203.
129. Deepe GS, Smelt S, Louie JS. Tumor necrosis factor inhibition and opportunistic infections. Clin Infect Dis 2005;41:187-8.
130. Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis 2005;41:208-12.
131. Moore TA, Lau HY, Cogen AL, Standiford TJ. Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF. Clin Infect Dis 2005;41:213-7.
132. CDC. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR 2004;53: 683-6.
133. Markert ML, Hummell DS, Rosenblatt HM, et al. Complete DiGeorge syndrome: persistence of profound immunodeficiency. J Pediatr 1998;132:15-21.
134. Anonymous. 110 Warning signs of primary immunodeficiency [Poster]. New York, NY: Jeffrey Modell Foundation Medical Advisory Board; 2004.
135. Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr 2006;148:842-4.
136. CDC. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2009;58(No. RR-2).
137. Sixbey JW. Routine immunization of the immunocompromised child. Adv Pediatr Infect Dis 1987;2:79-114.
138. Wright PF, Hatch MH, Kasselberg AG, Lowry SP, Wadlington WB, Karzon DT. Vaccine-associated poliomyelitis in a child with sex-linked agammaglobulinemia. J Pediatr 1977;91:408-12.
139. Wyatt HV. Poliomyelitis in hypogammaglobulinemics. J Infect Dis 1973;128:802-6.
140. Davis LE, Bodian D, Price D, Butler IJ, Vickers JH. Chronic progressive poliomyelitis secondary to vaccination of an immunodeficient child. N Engl J Med 1977;297:241-5.
141. CDC. Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. MMWR 1985;34:227-8.
142. Ninane J, Grymonprez A, Burtonboy G, Francois A, Cornu G. Disseminated BCG in HIV infection. Arch Dis Child 1988; 63:1268-9.
143. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987;316:673-6.
144. CDC. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR 1996;45: 603-6.
145. Derryck A, LaRussa P, Steinberg S, Capasso M, Pitt J, Gershon AA. Varicella and zoster infection in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1998;17:931-3.
146. CDC. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR 2009;58(No. RR-11).
147. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001;139:305-10.
148. Sprauer MA, Markowitz LE, Nicholson JKA, et al. Response of human immunodeficiency virus-infected adults to measles-rubella vaccination. J Acquir Immune Defic Syndr 1993;6:1013-6.
149. McLaughlin M, Thomas P, Onorato I, et al. Live virus vaccines in human immunodeficiency virus-infected children: a retrospective survey. Pediatrics 1988;82:229-33.
150. Onorato IM, Markowitz LE, Oxtoby MJ. Childhood immunization, vaccine-preventable diseases and infection with human immunodeficiency virus. Pediatr Infect Dis J 1988;6:588-95.
151. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992;11:1008-14.
152. Tomblyn M, Chiller T, Einsele et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant 15:1143-1238; 2009.
153. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009;44: 521-6.
154. American Academy of Pediatrics. Immunization in special clinical circumstances. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS. eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009.
155. Brodtman DH, Rosenthal DW, Redner A, Lanzkowsky P, Bonagura VR. Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. J Pediatr 2005;146:654-61.
156. Starr S, Berkovich S. Effects of measles, gamma-globulin-modified measles and vaccine measles on the tuberculin test. N Engl J Med 1964;270:386-91.
157. Brickman HF, Beaudry PH, Marks MI. Timing of tuberculin tests in relation to immunization with live viral vaccines. Pediatrics 1975;55: 392-6.
158. Berkovich S, Starr S. Effects of live type 1 poliovirus vaccine and other viruses on the tuberculin test. N Engl J Med 1966;274:67-72.
159. CDC. Recommendations for using smallpox vaccine in a pre-event vaccination program: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 2003;52(No. RR-7).
160. CDC. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR 2010;59(No. RR-5).
161. Grabenstein JD. Clinical management of hypersensitivities to vaccine components. Hospital Pharmacy 1997;32:77-87.
162. Grabenstein JD. ImmunoFacts: vaccines & immunologic drugs. St. Louis, MO: Wolters Kluwer;Facts & Comparisons; 2010.
163. Kelso JM. Administration of influenza vaccine to patients with egg allergy. J Allergy Clin Immunol 2010;125:800-2.
164. Wood RA, Berger M, Dreskin SC, et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008;122:e771-e7.
165. Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy Clin Immunol 1993;91:867-72.
166. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. J Allergy Clin Immunol 1995;96:563-5.
167. Sakaguchi M, Yamanaka T, Ikeda K, et al. IgE-mediated systemic reactions to gelatin included in the varicella vaccine. J Allergy Clin Immunol 1997;99:263-4.
168. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996;98:1058-61.
169. Reitschel RL, Bernier R. Neomycin sensitivity and the MMR vaccine [Letter]. JAMA 1981;245:571.
170. Elliman D, Dhanraj B. Safe MMR vaccination despite neomycin allergy [Letter]. Lancet 1991;337:365.
171. Aberer W. Vaccination despite thimerosal sensitivity. Contact Dermatitis 1991;24:6-10.
172. Kirkland LR. Ocular sensitivity to thimerosal: a problem with hepatitis B vaccine? South Med J 1990;83:497-9.
173. Cox NH, Forsyth A. Thiomersal allergy and vaccination reactions. Contact Dermatitis 1988;18:229-33.
174. Möller H. All these positive tests to thimerosal. Contact Dermatitis 1994;31:209-13.
175. Wantke F, Demmer CM, Götz M, Jarisch R. Contact dermatitis from thimerosal: 2 year's experience with ethylmercuric chloride in patch testing thimerosal-sensitive patients. Contact Dermatitis 1994;30: 115-8.
176. Slater JE. Latex allergy. J Allergy Clin Immunol 1994;94:139-49.
177. Towse A, O'Brien M, Twarog FJ, Braimon J, Moses A. Local reaction secondary to insulin injection: a potential role for latex antigens in insulin vials and syringes. Diabetes Care 1995;18:1195-7.
178. Bastyr EJ. Latex allergen allergic reactions [Letter]. Diabetes Care 1996;19:546.
179. MacCracken J, Stenger P, Jackson T. Latex allergy in diabetic patients: a call for latex-free insulin tops [Letter]. Diabetes Care 1996;19:184.
180. Russell M, Pool V, Kelso J, Tomazic-Jezic V. Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2004;23:664-7.
181. Bernbaum JC, Daft A, Anolik R, et al. Response of preterm infants to diphtheria-tetanus-pertussis immunizations. J Pediatr 1985;107: 184-8.
182. Koblin BA, Townsend TR, Munoz A, Onorato I, Wilson M, Polk BF. Response of preterm infants to diphtheria-tetanus-pertussis vaccine. Pediatr Infect Dis J 1988;7:704-11.
183. Smolen P, Bland R, Heiligenstein E, et al. Antibody response to oral polio vaccine in premature infants. J Pediatr 1983;103:917-9.
184. Omenaca F, Garcia-Sicilia J, Garcia-Corbeira P, et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 2005;116:1292-8.
185. Shinefield H, Black S, Ray P, Fireman B, Schwalee M, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birthweight preterm infants. Ped Inf Dis J 2002;21: 182-6.
186. Lau YL, Tam AY, Ng KW, et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992;121:962-5.
187. Patel DM, Butler J, Feldman S, Graves GR, Rhodes PG. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr 1997;131:641-3.
188. Kim SC, Chung EK, Hodinka RL, et al. Immunogenicity of hepatitis B vaccine in preterm infants. Pediatrics 1997;99:534-6.
189. Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics 1999;103:14.
190. Bohlke K, Galil K, Jackson LA, et al. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? Obstet Gynecol 2003;102: 970-7.
191. Krogh V, Duffy LC, Wong D, Rosenband M, Riddlesberger KR, Ogra PL. Postpartum immunization with rubella virus vaccine and antibody response in breast-feeding infants. J Lab Clin Med 1989;113:695-9.
192. Pickering LK, Granoff DM, Erickson JR, et al. Modulation of the immune system by human milk and infant formula containing nucleotides. Pediatrics 1998;101:242-9.
193. Kim-Farley R, Brink E, Orenstein W, Bart K. Vaccination and breast feeding [Letter]. JAMA 1982;248:2451-2.
194. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral polio vaccine in developing countries: review. Rev Infect Dis 1991;13:926-39.
195. Hahn-Zoric M, Fulconis F, Minoli I, et al. Antibody responses to parenteral and oral vaccines are impaired by conventional and low-protein formulas as compared to breast feeding. Acta Paediatr Scand 1990;79:1137-42.
196. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338: 1128-37.
197. Grabenstein JD. Vaccines and antibodies in relation to pregnancy and lactation. Hospital Pharmacy 1999;34:949-60.
198. CDC. Guiding principles for development of ACIP recommendations for vaccinating during pregnancy and breastfeeding. MMWR 2008;57: 580.
199. CDC. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57(No. RR-4).
200. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998;148:1094-102.
201. CDC. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-5).
202. CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-7).
203. Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 1993;168: 1520-3.
204. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR 2006; 55(No. RR-16)[1-33].
205. Wilson E, Goss MA, Marin M, et al. Varicella vaccine exposure during pregnancy: data from 10 years of the pregnancy registry. J Infect Dis 2008;197 (Suppl 2):S178-84.
206. CDC. Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR 2001;50:1117.
207. CDC. Rubella vaccination during pregnancy-United States, 1971-1988. MMWR 1989;38:289-93.
208. Murray TS, Groth E, Weitzman C, Cappello M. Epidemiology and management of infectious diseases in international adoptees. Clin Microbiol Rev 2005;18:510-20.
209. Hostetter MK. Infectious diseases in internationally adopted children: findings in children from China, Russia, and Eastern Europe. Adv Pediatr Infect Dis 1999;14:147-61.
210. Kriz B, Burian V, Sladky K, et al. Comparison of titration results of diphtheric antitoxic antibody obtained by means of Jensen's method and the method of tissue cultures and haemagglutination. J Hyg Epidemiol Microbiol Immunol 1978;22:485-93.
211. CDC. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR 2009;58.
212. CDC. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 2008;57(No. RR-8).
213. Evans DI, Shaw A. Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs. BMJ 1990;300:1694-5.
214. CDC. Immunization information system progress-United States, 2006. MMWR 2008;57:289-91.
215. US Department of Health and Human Services, Health Care Financing Administration; DeParle N, ed. A profile of Medicaid: chartbook 2000. Washington, DC: Health Care Financing Administration. Available at http://www.cms.hhs.gov/thechartseries. Accessed December 13, 2010.
216. US Department of Health and Human Services. Immunization and infectious diseases. In: Healthy people 2010 (conference ed., vol. 1). Washington, DC: US Government Printing Office; 2000.
217. Mangione-Smith R, DeChristofaro A, Setodji C, et al. The quality of ambulatory care delivered to children in the United States. NEJM 2007; 375:1515-23.
218. Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298:2155-63.
219. CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Notice to readers: Programmatic strategies to increase vaccination coverage by age 2 years-linkage of vaccination and WIC services. MMWR 1996;45:217-8.
220. Hagan JF, Shaw JS, Duncan PM, eds. Bright futures: guidelines for health supervision on infants, children and adolescents. 3rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2008.
221. CDC. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American Medical Association (AMA). MMWR 1996;45(No. RR-13).
222. Poland GA, Shefer AM, McCauley M, et al. Standards for adult immunization practices. Am J Prev Med 2003;25:144-50.
223. Maciosek MV, Coffield AB, Edwards NM, et al. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med. 2006;31:52-61.
224. Riddiough MA, Sisk JE, Bell JC. Influenza Vaccination. JAMA 1983;249:3189-95.
225. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161: 749-59.
226. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003;21:2207-17.
227. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000;284:1655-63.
228. Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008; 26:1420-31.
229. Pisu M, Meltzer MI, Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 2002;21:312-21.
230. Rich JD, Ching CG, Lally MA, et al. A review of the case for hepatitis B vaccination of high-risk adults. Am J Med 2003; 114:316-8.
231. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007;25:8326-37.
232. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748-53.
233. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280-8.
234. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006;145:317-25.
235. Shefer A, Briss P, Rodewald L, et al. Improving immunization coverage rates: an evidence-based review of the literature. Epidemiol Rev 1999;21:96-142.
236. CDC. Vaccine-preventable diseases: improving vaccination coverage in children, adolescents, and adults; a report on recommendations of the Task Force on Community Preventive Services. MMWR 1999;48(No. RR-8).
237. Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med 2000;18:97-140.
238. Task Force on Community Preventive Services. Recommendations regarding interventions to improve vaccination coverage in children, adolescents, and adults. Am J Prev Med 2000;18:92-6.
239. Ndiaye SM, Hopkins DP, Shefer AM, et al. Interventions to improve influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among high-risk adults: a systematic review. Am J Prev Med. 2005;28(Suppl 5):248-79.